SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Klein Saskia K.)
 

Sökning: WFRF:(Klein Saskia K.) > Addition of lenalid...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00008033naa a2200889 4500
001oai:DiVA.org:uu-440998
003SwePub
008210426s2021 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4409982 URI
0247 a https://doi.org/10.1182/bloodadvances.20200038552 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Löwenberg, Bobu Erasmus Univ Med Ctr MC, Rotterdam, Netherlands.;Erasmus MC Canc Inst, Rotterdam, Netherlands.4 aut
2451 0a Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML :b the HOVON-SAKK-132 trial
264 c 2021-02-22
264 1b American Society of Hematology,c 2021
338 a print2 rdacarrier
520 a Lenalidomide, an antineoplastic and immunomodulatory drug, has therapeutic activity in acute myeloid leukemia (AML), but definitive studies about its therapeutic utility have been lacking. In a phase 3 study, we compared 2 induction regimens in newly diagnosed patients age 18 to 65 years with AML: idarubicine-cytarabine (cycle 1) and daunorubicin and intermediate-dose cytarabine (cycle 2) without or with lenalidomide (15 mg orally on days 1-21). One final consolidation cycle of chemotherapy or autologous stem cell transplantation (auto-SCT) or allogeneic SCT (allo-SCT) was provided according to a prognostic risk and minimal residual disease (MRD)-adapted approach. Event-free survival (EFS; primary end point) and other clinical end points were assessed. A second random assignment in patients in complete response or in complete response with incomplete hematologic recovery after cycle 3 or auto-SCT involved 6 cycles of maintenance with lenalidomide (10 mg on days 1-21) or observation. In all, 392 patients were randomly assigned to the control group, and 388 patients were randomly assigned to lenalidomide induction. At a median follow-up of 41 months, the study revealed no differences in outcome between the treatments (EFS, 44% +/- 2% standard error and overall survival, 54% = 2% at 4 years for both arms) although in an exploratory post hoc analysis, a lenalidomide benefit was suggested in SRSF2-mutant AML. In relation to the previous Dutch-Belgian Hemato-Oncology Cooperative Group and Swiss Group for Clinical Cancer Research (HOVON-SAKK) studies that used a similar 3-cycle regimen but did not pursue an MRD-guided approach, these survival estimates compare markedly more favorably. MRD status after cycle 2 lost prognostic value in intermediate-risk AML in the risk-adjusted treatment context. Maintenance with lenalidomide showed no apparent effect on relapse probability in 88 patients randomly assigned for this part of the study.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Pabst, Thomasu Inselspital Bern, Bern, Switzerland.4 aut
7001 a Maertens, Johanu Univ Hosp Gasthuisberg, Leuven, Belgium.4 aut
7001 a Gradowska, Patrycjau Erasmus MC Canc Inst, Dutch Belgian Hematooncol Cooperat Grp Data Ctr, Rotterdam, Netherlands.4 aut
7001 a Biemond, Bart J.u Amsterdam Univ Med Ctr, Amsterdam, Netherlands.4 aut
7001 a Spertini, Olivieru Univ Lausanne UNIL, Lausanne Univ Hosp, Ctr Hosp Univ Vaudois, Lausanne, Switzerland.4 aut
7001 a Vellenga, Edou Univ Groningen, Univ Med Ctr, Groningen, Netherlands.4 aut
7001 a Griskevicius, Laimonasu Vilnius Univ Hosp, Santaros Klin, Vilnius, Lithuania.;Vilnius Univ, Vilnius, Lithuania.4 aut
7001 a Tick, Lidwine W.u Maxima Med Ctr, Eindhoven, Netherlands.4 aut
7001 a Jongen-Lavrencic, Mojcau Erasmus Univ Med Ctr MC, Rotterdam, Netherlands.;Erasmus MC Canc Inst, Rotterdam, Netherlands.4 aut
7001 a Kooy, Marinus van Marwijku Isala Hosp, Zwolle, Netherlands.4 aut
7001 a Vekemans, Marie-Christianeu Univ Hosp St Luc, Brussels, Belgium.4 aut
7001 a van der Velden, Walter J. F. M.u Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands.4 aut
7001 a Beverloo, Bernau Erasmus Univ MC, Dept Clin Genet, Rotterdam, Netherlands.4 aut
7001 a Michaux, Lucienneu Katholieke Univ Leuven, Ctr Human Genet, Leuven, Belgium.;Univ Hosp Leuven, Leuven, Belgium.4 aut
7001 a Graux, Carlosu Univ Catholique Louvain Namur Godinne, Yvoir, Belgium.4 aut
7001 a Deeren, Driesu AZ Delta, Roeselare, Belgium.4 aut
7001 a de Weerdt, Okkeu St Antonius Hosp, Nieuwegein, Netherlands.4 aut
7001 a van Esser, Joost W. J.u Amphia Hosp, Breda, Netherlands.4 aut
7001 a Bargetzi, Mariou Kantonsspittal, Aarau, Switzerland.4 aut
7001 a Klein, Saskia K.u Meander Med Ctr, Amersfoort, Netherlands.4 aut
7001 a Gadisseur, Alainu Univ Hosp Antwerpen, Edegem, Belgium.4 aut
7001 a Westerweel, Peter E.u Albert Schweitzer Hosp, Dordrecht, Netherlands.4 aut
7001 a Veelken, Hendriku Univ Med Ctr, Leiden, Netherlands.4 aut
7001 a Gregor, Michaelu Luzerner Kantonsspittal, Luzern, Switzerland.4 aut
7001 a Silzle, Tobiasu Kantonsspittal, St Gallen, Switzerland.4 aut
7001 a Van Lammeren-Venema, Danielleu Haga Hosp, The Hague, Netherlands.4 aut
7001 a Moors, Ineu Univ Hosp, Ghent, Belgium.4 aut
7001 a Breems, Dimitri A.u Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium.4 aut
7001 a Hoogendoorn, Melsu Med Spectrum Leeuwarden, Leeuwarden, Netherlands.4 aut
7001 a Legdeur, Marie-Cecile J. C.u Med Spectrum Twente, Enschede, Netherlands.4 aut
7001 a Fischer, Thomasu Otto von Guericke Univ Hosp Magdeburg, Magdeburg, Germany.4 aut
7001 a Kuball, Juergenu Univ Med Ctr Utrecht, Utrecht, Netherlands.4 aut
7001 a Cornelissen, Janu Erasmus Univ Med Ctr MC, Rotterdam, Netherlands.;Erasmus MC Canc Inst, Rotterdam, Netherlands.4 aut
7001 a Porkka, Kimmou Helsinki Univ Hosp Canc Ctr, Helsinki, Finland.4 aut
7001 a Juliusson, Gunnaru Skanes Univ Hosp, Lund, Sweden.4 aut
7001 a Meyer, Peteru Stavanger Univ Hosp Rogaland, Stavanger, Norway.4 aut
7001 a Höglund, Martinu Uppsala universitet,Hematologi4 aut0 (Swepub:uu)martinhl
7001 a Gjertsen, Bjorn T.u Haukeland Hosp, Bergen, Norway.4 aut
7001 a Janssen, Jeroen J. W. M.u Amsterdam Vrije Univ, Med Ctr, Amsterdam, Netherlands.4 aut
7001 a Huls, Gerwinu Univ Groningen, Univ Med Ctr, Groningen, Netherlands.4 aut
7001 a Passweg, Jakobu Univ Hosp, Basel, Switzerland.4 aut
7001 a Cloos, Jacquelineu Amsterdam Vrije Univ, Med Ctr, Amsterdam, Netherlands.4 aut
7001 a Valk, Peter J. M.u Erasmus Univ Med Ctr MC, Rotterdam, Netherlands.;Erasmus MC Canc Inst, Rotterdam, Netherlands.4 aut
7001 a van Elssen, Catharina H. M. J.u Univ Med Ctr, Maastricht, Netherlands.4 aut
7001 a Manz, Markus G.u Univ Hosp, Zurich, Switzerland.4 aut
7001 a Floisand, Yngvaru Oslo Univ Hosp, Oslo, Norway.4 aut
7001 a Ossenkoppele, Gert J.u Amsterdam Vrije Univ, Med Ctr, Amsterdam, Netherlands.4 aut
7102 a Erasmus Univ Med Ctr MC, Rotterdam, Netherlands.;Erasmus MC Canc Inst, Rotterdam, Netherlands.b Inselspital Bern, Bern, Switzerland.4 org
7730 t Blood Advancesd : American Society of Hematologyg 5:4, s. 1110-1121q 5:4<1110-1121x 2473-9529x 2473-9537
8564 u https://ashpublications.org/bloodadvances/article-pdf/5/4/1110/1800710/advancesadv2020003855.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-440998
8564 8u https://doi.org/10.1182/bloodadvances.2020003855

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy